I recently had the privilege of engaging in an enlightening conversation with Dave Hanaman, the co-founder of Curavit. Our conversation covered a wide array of topics, ranging from recent achievements to industry trends and the future trajectory of clinical research.
Since our last discussion, Curavit has achieved a series of significant milestones, reflecting what they describe as their ‘unwavering commitment to excellence and innovation’. Hanaman eagerly shared their continued success in securing partnerships with solid clients, including MedRhythms, a pioneering company in the realm of music therapy trials.
“We’ve got another partnership since I saw you last with MedRhythms, which is doing music therapy and we’ve got another trial coming up with them,” Hanaman said.
MedRhythms’ neurorehabilitation system is designed to improve walking and ambulation in adults with chronic stroke walking impairments. The goal of the study is to further characterize the long-term economic and clinical benefits beyond what has been established in a multi-center, randomized clinical trial. This will also include evaluating patient engagement and therapeutic response durability.
Furthermore, Curavit recently concluded a highly successful PTSD study in collaboration with the Sana devive, earning accolades and advancing with the FDA.
Hanaman said: “We just completed a PTSD study with Sana that was successful, and they got recognition for that and are moving forward with the FDA. So, we were proud to be a small part of that.”
Of note is Curavit’s partnership with an unnamed major pharmaceutical company on a trial involving a digital solution. Hanaman touched upon this seminal collaboration, emphasizing its significance in bridging the gap between traditional pharmaceuticals and emerging digital health solutions.
An exciting development for Curavit has been its foray into health economics and outcomes research (HEOR), a strategic move aimed at enhancing the evaluation of treatment efficacy and financial viability. Hanaman shed light on their approach, explaining, “The work we’re doing with MedRhythms includes bringing in real-world data to analyze to also study the financial model and efficacy of the treatment.”
In discussing Curavit’s growth strategy, Hanaman underscored its anticipation of significant expansion across various sectors, including digital therapeutics and emerging pharmaceuticals. He articulated, “We’re anticipating significant growth… We’ve got a really healthy pipeline in both digital therapeutics and emerging pharma.”
A cornerstone of Curavit’s innovative approach to clinical trials is its virtual site capabilities, which Hanaman described as indispensable for conducting decentralized trials. He elaborated, “it’s basically a requirement… It’s a fundamental platform that supports doing a decentralized trial.”
Looking ahead, Hanaman expressed optimism about the future landscape of clinical trials, citing a supportive regulatory environment and increasing industry collaboration as catalysts for innovation. However, he cautioned against excessive regulation, advocating for clear, well-enforced guidelines to ensure transparency and efficiency in trial conduct.
In conclusion, my conversation with Dave Hanaman shed light on Curavit’s dedication to pushing the boundaries of clinical research. As they continue to devise novel approaches and forge strategic partnerships, Curavit says it is poised to drive transformative change in the field of healthcare and clinical trials.
